Buscar
Novavax Inc
NVAXAñadir a la lista de seguimiento
7.320USD
-0.120-1.61%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.20BCap. mercado
PérdidaP/E TTM
Más Datos de Novavax Inc Compañía
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Información de Novavax Inc
Símbolo de cotizaciónNVAX
Nombre de la empresaNovavax Inc
Fecha de salida a bolsaMay 16, 1973
Director ejecutivoJacobs (John C)
Número de empleados952
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 16
Dirección21 Firstfield Rd
CiudadGAITHERSBURG
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20878
Teléfono12402682000
Sitio Webhttps://www.novavax.com/?locale=US
Símbolo de cotizaciónNVAX
Fecha de salida a bolsaMay 16, 1973
Director ejecutivoJacobs (John C)
Ejecutivos de Novavax Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
306.56K
--
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
134.64K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
98.65K
+19.14%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
92.10K
+20.50%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
90.07K
--
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
66.25K
+28.50%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
62.95K
+29.99%
Dr. Ruxandra Draghia-Akli, M.D., Ph.D.
Dr. Ruxandra Draghia-Akli, M.D., Ph.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
23.56K
--
Mr. Gregg Huber Alton, J.D.
Mr. Gregg Huber Alton, J.D.
Independent Director
Independent Director
--
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
306.56K
--
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
134.64K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
98.65K
+19.14%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
92.10K
+20.50%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
90.07K
--
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
66.25K
+28.50%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Novavax Inc?
Los cinco principales accionistas de Novavax Inc son: Mr. John C. Jacobs
¿Cuántas instituciones poseen acciones de Novavax Inc (NVAX)?
A fecha de 2026Q1, 557 instituciones poseen acciones de Novavax Inc, con un valor de mercado combinado de aproximadamente 128.09M, lo que representa el 77.98% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 7284856.00.
¿Cuál es la mayor fuente de ganancias de Novavax Inc?
El 2026Q1, el segmento empresarial Product generó la ganancia más alta para Novavax Inc, ascendiendo a 685.04M y representando el 60.97% de la ganancia total.